How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Dystrophin Market
- By Product Type: Recombinant Dystrophin Protein, Dystrophin Gene Therapy Vectors, Antisense Oligonucleotides Targeting Dystrophin, Dystrophin Expression Assays, Dystrophin Antibodies
- By Application: Duchenne Muscular Dystrophy (DMD) Treatment, Becker Muscular Dystrophy (BMD) Treatment, Diagnostic Testing for Muscular Dystrophies, Research and Development, Gene Editing Therapies
- By End User: Pharmaceutical and Biotechnology Companies, Research Laboratories, Hospitals and Clinics, Diagnostic Laboratories, Academic and Research Institutions
- By Therapeutic Approach: Gene Replacement Therapy, Exon Skipping Therapy, Stop Codon Read-Through Therapy, Cell Therapy, CRISPR/Cas9 Gene Editing
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Recombinant Dystrophin Protein leads By Product Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 14 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 279 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.170 →
- 11 Company Profiles 14 players: SWOT & benchmarking p.178 →
Full report · locked preview
Everything inside the Dystrophin Market report
A complete, evidence-based study - 11 chapters and 117 sections covering market size, segmentation across 4 axes, regional analysis and 14 company profiles, forecast to 2033.
Segmentation covered
Product Type 5
Application 5
End User 5
Therapeutic Approach 5
Companies profiled
Sarepta Therapeutics
Pfizer Inc.
Solid Biosciences
Capricor Therapeutics
Wave Life Sciences
PTC Therapeutics
Catabasis Pharmaceuticals
Biogen Inc.
Dynacure
Audentes Therapeutics
Roche
Santhera Pharmaceuticals
+2 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
14 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Sarepta Therapeutics
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Pfizer Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Solid Biosciences
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Capricor Therapeutics
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Wave Life Sciences
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →PTC Therapeutics
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Catabasis Pharmaceuticals
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Biogen Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Dynacure
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Audentes Therapeutics
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Roche
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Santhera Pharmaceuticals
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.220 →NS Pharma
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Italfarmaco
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$11,783M by 2033 · 10.5% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Recombinant Dystrophin Protein51.2
- Dystrophin Gene Therapy Vectors15.8
- Antisense Oligonucleotides Targeting Dystrophin8.5
- Dystrophin Expression Assays12.6
- Dystrophin Antibodies12.0
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,749M → $3,989M · 10.9%
Europe$1,219M → $2,588M · 9.9%
Asia Pacific$1,113M → $2,254M · 9.2%
Latin America$689.1M → $1,693M · 11.9%
Middle East and Africa$530.1M → $1,262M · 11.5%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →10.462026
10.472027
10.482028
10.492029
10.492030
10.522031
10.522032
10.532033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Sarepta Therapeutics26.5
- Pfizer Inc.12.5
- Solid Biosciences4.9
- Capricor Therapeutics6.0
- Wave Life Sciences13.2
- PTC Therapeutics8.9
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Product Type33.8%
Application15.6%
End User13.1%
Therapeutic Approach37.5%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America33.8
- Europe22.0
- Asia Pacific19.1
- Latin America14.4
- Middle East and Africa10.7
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Sarepta Therapeutics | 82 | 86 | 90 | 94 | 77 | 79 | 85 |
| Pfizer Inc. | 83 | 69 | 76 | 78 | 90 | 82 | 80 |
| Solid Biosciences | 85 | 79 | 83 | 80 | 66 | 73 | 78 |
| Capricor Therapeutics | 67 | 81 | 65 | 68 | 68 | 76 | 71 |
| Wave Life Sciences | 70 | 76 | 63 | 66 | 74 | 71 | 70 |
| PTC Therapeutics | 57 | 55 | 56 | 62 | 49 | 53 | 55 |
| Catabasis Pharmaceuticals | 53 | 64 | 54 | 46 | 52 | 63 | 55 |
| Biogen Inc. | 55 | 47 | 49 | 50 | 54 | 39 | 49 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Sarepta Therapeutics
- Pfizer Inc.
- Solid Biosciences
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Sarepta Therapeutics | ◐ | ◐ | ✓ | ✓ | ✓ | ◐ |
| Pfizer Inc. | ◐ | ✓ | ◐ | ✓ | ◐ | ◐ |
| Solid Biosciences | ◐ | ✓ | ✓ | ✓ | ◐ | ◐ |
| Capricor Therapeutics | ◐ | ◐ | ◐ | ✓ | ◐ | ◐ |
| Wave Life Sciences | ◐ | ✓ | − | ◐ | ✓ | ◐ |
| PTC Therapeutics | − | ◐ | − | ◐ | ◐ | − |
| Catabasis Pharmaceuticals | − | ◐ | ◐ | ◐ | ◐ | ◐ |
| Biogen Inc. | ◐ | − | − | ◐ | ◐ | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Sarepta Therapeutics85
2Pfizer Inc.80
3Solid Biosciences78
4Capricor Therapeutics71
5Wave Life Sciences70
6PTC Therapeutics55
7Catabasis Pharmaceuticals55
8Biogen Inc.49
Competitive tiers
§8.4 · p.172 →Leader3
Set the pace on share, breadth and innovation.
Sarepta TherapeuticsPfizer Inc.Solid Biosciences
Challenger2
Strong scale, closing on the leaders.
Capricor TherapeuticsWave Life Sciences
Niche3
Specialists in a single segment or region.
PTC TherapeuticsCatabasis PharmaceuticalsBiogen Inc.
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Product Type in North America, then scale across Dystrophin Market — a $75M beachhead inside a $1.23B market.
Beachhead (SOM)$75Mobtainable near-term
Serviceable (SAM)$460Mreachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion91 fit
Recombinant Dystrophin Protein
Best fit — highest urgency & budget in Product Type.
Economic buyer76 fit
Dystrophin Gene Therapy Vectors
Strong fit — clear ROI and a fast path to value.
End user69 fit
Antisense Oligonucleotides Targeting Dystrophin
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Product Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Application & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales44%
Partner / channel29%
Digital / self-serve18%
Marketplaces9%
Positioning & messaging
§GTM 2 · p.194 →For Product Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Dystrophin Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified43%
Sales qualified20%
Evaluation15%
Closed-won7%
$14.4KCAC
$56KLTV
3.9:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Dystrophin Market is a durable-growth opportunity — $9.71B by 2033, compounding at 7.2%.
TAM · 2025$5.59Btoday
TAM · 2033$9.71Bforecast
CAGR7.2%2027–2033
Cumulative$67.4Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$9.71BTotal addressable market
SAM$3.87BServiceable available market
SOM$649MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →7.2% CAGR
Demand compounds through 2033, outpacing GDP across Product Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Product Type moving from early to mainstream — durable secular demand.
Consolidation upside
14+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$9.71BLarge & growingTAM by 2033 at 7.2% CAGR
$3.87BServiceable nowreachable with today’s model
$649MBeachhead winobtainable near-term share
14+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$7.58BBear4.7% CAGR
$9.71BBase7.2% CAGR
$12.4BBull9.5% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Application optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Dystrophin Market — a $4.84B market by 2033. Plan: grow share from 8.6% to 14.5%.
Market size · 2033$4.84Btotal addressable
Market CAGR3.2%2027–2033
Target share14.5%from 8.6% today
Revenue ambition$702Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 8.6% | 14.5% | Behind |
| Revenue | $380M | $702M | Behind |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | At risk |
| Gross margin | 36.1% | 38.0% | On track |
| Customer retention | 87.8% | 95.7% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Product Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Application capability
A defensible second engine — invest in Application to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Product Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Application
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $89M capacity & capability investment
- Greenlight bolt-on M&A in Application
- Authorise North America expansion plan
- Fund R&D program for Product Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAhead
- Competitive share lossBehind
- Input-cost & supply riskAhead
- Regulatory / policy changeBehind
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Dystrophin Market conversation — a $3.21B market you can size, segment and defend in minutes.
Market size · 2033$3.21Btotal opportunity
Growth3.8%CAGR to 2033
Addressable buyers1,523+accounts in scope
Typical ROI5.8×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Product Type
Goal Grow share in Product Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5.8×return on cost, year one
< 4 mopayback period
$44K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
14+players profiled in this market
Coverage includes
Sarepta TherapeuticsPfizer Inc.Solid BiosciencesCapricor TherapeuticsWave Life SciencesPTC TherapeuticsCatabasis PharmaceuticalsBiogen Inc.+6 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Dystrophin Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Dystrophin Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Antidiabetic SGLT-2 Inhibitor Market
Market size, share, segmentation and regional forecast.
$1.4B market · 2025 base year
View reportContrast Agents for Magnetic Resonance Imaging (MRI) Market
Market size, share, segmentation and regional forecast.
$377M market · 2025 base year
View reportAmyloidosis Therapeutics Market
Market size, share, segmentation and regional forecast.
$3.0B market · 2025 base year
View reportBromodomain Containing Protein 4 Market
Market size, share, segmentation and regional forecast.
$327M market · 2025 base year
View reportChoroidal Neovascularization Drug Market
Market size, share, segmentation and regional forecast.
$2.3B market · 2025 base year
View reportDigestive Health Enzymes Market
Market size, share, segmentation and regional forecast.
$4.7B market · 2025 base year
View reportMetabotropic Glutamate Receptor Market
Market size, share, segmentation and regional forecast.
$2.5B market · 2025 base year
View reportAlcohol Addiction Therapeutics Market
Market size, share, segmentation and regional forecast.
$3.1B market · 2025 base year
View reportH3N2 Infection Treatment Market
Market size, share, segmentation and regional forecast.
$4.2B market · 2025 base year
View reportVasculitis Drug Market
Market size, share, segmentation and regional forecast.
$1.2B market · 2025 base year
View reportRAC Gamma Serine/Threonine Protein Kinase Market
Market size, share, segmentation and regional forecast.
$5.4B market · 2025 base year
View reportHistone Deacetylase 2 Market
Market size, share, segmentation and regional forecast.
$2.3B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.